In the morning edition of Chunichi Shimbun on October 15th, 2020 (Page 3), the conclusion of the research collaboration agreement between Rebirthel and Fujita Health University was reported.
The article is entitled “Fujita Health University will develop a therapy for the novel coronavirus infection using killer T cells – aiming to start a clinical trial within 2 to 3 years”. Killer T cell will be regenerated from iPS cells in which coronavirus-specific TCR is transferred, and be administered to patients as transfusion. Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University) explains that this technology can be expanded to target other infectious diseases.
Rebirthel has made the press release to announce this agreement on October 14th, 2020.
Link to the article (Only for members and only in Japanese)